Discover ingredient solutions for sugar reduction, fiber enrichment and plant-based proteins to meet GLP-1-driven consumer demands
The side effects of these drugs are not fully known, particularly longer-term ones, another reason payers may delay their decision-making process as regards to the current weight-loss drugs, Rayburg said
For surgery, the timing conversation involves your surgical team
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
The authors commented that in some cases, the dose had to be decreased from 20 g per day to 10 g per day, due to side effects
What happens if my FeelGood provider says I'm not eligible
